Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Dexamethasone, and Rituximab (IDR) in Untreated Waldenstrom's Macroglobulinemia
NCT02400437Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2015
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in Waldenström macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Apr 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02400437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400437.